Testing effectiveness (Phase 2)Looking for participantsNCT05746208
What this trial is testing
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Who this might be right for
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco 29